Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
2024

New Treatment for Bone Disease in Multiple Myeloma

Sample size: 10 publication 10 minutes Evidence: high

Author Information

Author(s): Hose Dirk, Ray Seemun, Rößler Sina, Thormann Ulrich, Schnettler Reinhard, de Veirman Kim, El Khassawna Thaqif, Heiss Christian, Hild Anne, Zahner Daniel, Alagboso Francisca, Henss Anja, Beck Susanne, Emde-Rajaratnam Martina, Burhenne Jürgen, Bamberger Juliane, Menu Eline, de Bruyne Elke, Gelinsky Michael, Kampschulte Marian, Rohnke Marcus, Wenisch Sabine, Vanderkerken Karin, Hanke Thomas, Seckinger Anja, Alt Volker

Primary Institution: Vrije Universiteit Brussel

Hypothesis

Can silica-collagen xerogels effectively treat osteolytic bone disease and minimal residual disease in multiple myeloma?

Conclusion

The study suggests that silica-collagen xerogels can stabilize bone defects, promote healing, and control tumor growth in multiple myeloma.

Supporting Evidence

  • Silica-collagen xerogels showed primary stability comparable to trabecular bone.
  • Both materials reduced osteoclast activity and did not negatively interfere with osteoblast function.
  • Enhanced bone formation was observed in vivo in a rat bone defect model.
  • Both materials induced myeloma cell apoptosis in all tested human myeloma cell lines.
  • Local control of malignant plasma cell growth was achieved in the 5T33-myeloma mouse model.

Takeaway

Researchers created special gels that can help heal bones and fight cancer in patients with a type of blood cancer called multiple myeloma.

Methodology

The study involved developing silica-collagen xerogels and testing their effects on bone formation and myeloma cell activity in vitro and in vivo using animal models.

Potential Biases

Potential bias in the selection of animal models and the assessment of outcomes.

Limitations

The study primarily focused on animal models, which may not fully replicate human responses.

Participant Demographics

Included patients with multiple myeloma, some of whom were refractory to systemic treatment.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/s13045-024-01636-4

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication